NorthWest Biotherapeutics Inc (NWBO)

[Bright Boy]

This is Bio's comment on the current patent held by Northwest that places Northwest in such a dynamic position!!!

biosectinvestor
RE: dennisdave Post # 495500

Post#
495501
of 495845
07/16/2022 05:08 AM
Not true. The patent is not linked to Merck at all, it is for ANY checkpoint inhibitor, and other immunotherapies, not just Keytruda. It's about mechanisms, not particular drugs and Keytruda is just one of many drugs that happens to be a checkpoint inhibitor or a PD1/PD-L1 inhibitor.

Granted, to use specifically Keytruda, the branded drug, they would need a license when they go for that deal. But Keytruda and others can't block DCVax by using their drug with a dendritic cell vaccine, defined broadly.

Moreover, when Keytruda's or other's patents expire, DCVax can then use DCVax with those drugs without inhibition.

Or, in the alternative, Merck or another large drug company buys NWBO and gets exclusive use of that patent to combine as they wish, and to access DCVax and even possibly other dendritic cell drugs that might fall under the patent, in combination with Keytruda or whatever other immunotherapy drugs they may have that also fall under the patent, which can also be expanded if the USPTO limits this one on the first pass in any significant manner. The patent is quite broad.



As GGB said, this is a "Kingmaker" !!!! All CPI's need DCVax-L to be extremely therapeutic!!! Once approved, all roads will lead to DCVax-L and Northwest!!!

Cheers,

BB